NEM · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $22.67B | $18.68B | $11.81B | $11.91B | $12.22B | $11.50B | $9.74B | $7.25B |
| Research & Development | $166.00M | $197.00M | $200.00M | $229.00M | $154.00M | $122.00M | $150.00M | $153.00M |
| Selling, General & Administrative | $382.00M | $442.00M | $299.00M | $276.00M | $259.00M | $269.00M | $313.00M | $244.00M |
| Operating Expenses | $11.71B | $14.15B | $13.51B | $11.71B | $10.96B | $8.69B | $8.46B | $6.46B |
| Other Income / (Expense) | $381.00M | $50.00M | -$331.00M | -$254.00M | -$149.00M | $337.00M | $2.42B | -$52.00M |
| Income Before Taxes | $11.34B | $4.58B | -$2.03B | -$51.00M | $1.11B | $3.14B | $3.69B | $738.00M |
| Provision for Income Taxes | $4.60B | $1.40B | $526.00M | $455.00M | $1.10B | $704.00M | $832.00M | $386.00M |
| Net Income | $7.08B | $3.35B | -$2.49B | -$429.00M | $1.17B | $2.83B | $2.81B | $341.00M |
| Basic EPS | $6.41 | $2.92 | -$2.97 | -$0.54 | $1.46 | $3.52 | $3.82 | $0.64 |
| Diluted EPS | $6.39 | $2.92 | -$2.97 | -$0.54 | $1.46 | $3.51 | $3.81 | $0.64 |
| Basic Shares Outstanding | 1.11B | 1.15B | 841.00M | 794.00M | 799.00M | 804.00M | 735.00M | 533.00M |
| Diluted Shares Outstanding | 1.11B | 1.15B | 841.00M | 795.00M | 801.00M | 806.00M | 737.00M | 535.00M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $9.06 | $8.61 | $9.55 | 8 | ↑1 ↓6 |
| Dec 2027 | $9.95 | $8.16 | $12.09 | 8 | ↑1 ↓6 |
| Dec 2028 | $11.78 | $10.14 | $14.24 | 4 | ↑0 ↓0 |
| Dec 2029 | $13.86 | $13.86 | $13.86 | 1 | ↑0 ↓0 |